- Home
- CB vs BMY Comparison
CB vs BMY Comparison
Compare CB & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CB | BMY |
|---|---|---|
| Founded | 1985 | 1887 |
| Country | Switzerland | United States |
| Employees | N/A | 34100 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.5B | 114.0B |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | CB | BMY |
|---|---|---|
| Price | $329.55 | $57.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 14 |
| Target Price | ★ $316.88 | $58.21 |
| AVG Volume (30 Days) | 1.6M | ★ 12.5M |
| Earning Date | 02-03-2026 | 02-05-2026 |
| Dividend Yield | 1.24% | ★ 4.50% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 23.94 | 2.97 |
| Revenue | ★ $58,842,000,000.00 | $48,034,000,000.00 |
| Revenue This Year | N/A | $0.27 |
| Revenue Next Year | $4.65 | N/A |
| P/E Ratio | ★ $13.09 | $18.85 |
| Revenue Growth | ★ 7.43 | 1.26 |
| 52 Week Low | $263.14 | $42.52 |
| 52 Week High | $316.94 | $63.33 |
Technical Indicators
Market Signals| Indicator | CB | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 77.13 | 66.23 |
| Support Level | $299.09 | $54.21 |
| Resistance Level | $305.75 | $56.12 |
| Average True Range (ATR) | 5.65 | 1.14 |
| MACD | 2.19 | 0.03 |
| Stochastic Oscillator | 88.38 | 94.34 |
Price Performance
Historical ComparisonAbout CB Chubb Limited
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.